The primary objective of this trial is to determine the efficacy of interleukin-15 (IL-15) inhibition with AMG 714 at inducing facial repigmentation in vitiligo.~The secondary objectives are to:~-Evaluate the safety and tolerability of AMG 714 in vitiligo- -Determine the efficacy of IL-15 inhibition with AMG 714 at inducing total body skin repigmentation in vitiligo-~Assess the durability of the skin repigmentation achieved by AMG 714 in vitiligo, and~Evaluate the efficacy of AMG 714 followed by narrow band UVB (nbUVB) phototherapy.
This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.